Intensity Modulated Radiotherapy With Concomitant Boost in Breast Cancer

IRCCS Azienda Ospedaliero-Universitaria di Bologna451 enrolled

Overview

To assess feasibility of postoperative IMRT with concomitant boost in moderate-high risk breast cancer in terms of late toxicity and local control

Patients treated conservatively with moderate-high risk breast cancer were treated with IMRT plus concomitant boost to surgical bed (up to a dose of 50 Gy to whole breast and 60 Gy to the tumor bed). Aim of the study was to evaluate late toxicity and local control after this treatment compared with a historical control group (CG) of patients treated with 3D-conformal postoperative radiotherapy delivered with conventional fractionation.

Study Type

OBSERVATIONAL

Enrollment

451

Conditions

Breast Cancer Radiation Toxicity

Interventions

IMRT with concomitant boostRADIATION

3D-RT with sequential boostRADIATION

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * histologically confirmed invasive breast cancer (pT1-4) with at least one of these characteristics: 3 or more metastatic axillary nodes, pre or peri-menopausal status, close resection margins * breast conservative surgery Exclusion Criteria: * positive margins * distant metastases

Outcomes

Primary Outcomes

Incidence of treatment.related late adverse events

late toxicity (cutaneous and subcutaneous) is evaluated using RTOG/EORTC criteria in both groups of patients

Time frame: 5 years

Secondary Outcomes

Local control

absence of locoregional relapse

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.